Raymond James & Associates’s Tenet Healthcare THC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $21.7M | Buy |
130,485
+26,011
| +25% | +$3.93M | 0.01% | 776 |
|
|
2024
Q2 | $13.9M | Buy |
104,474
+29,781
| +40% | +$3.58M | 0.01% | 974 |
|
|
2024
Q1 | $7.85M | Sell |
74,693
-18,434
| -20% | -$1.66M | 0.01% | 1296 |
|
|
2023
Q4 | $7.04M | Sell |
93,127
-42,350
| -31% | -$2.68M | 0.01% | 1317 |
|
|
2023
Q3 | $8.93M | Buy |
135,477
+32,992
| +32% | +$2.47M | 0.01% | 1099 |
|
|
2023
Q2 | $8.34M | Buy |
102,485
+22,170
| +28% | +$1.58M | 0.01% | 1165 |
|
|
2023
Q1 | $4.77M | Buy |
80,315
+3,716
| +5% | +$207K | ﹤0.01% | 1492 |
|
|
2022
Q4 | $3.74M | Sell |
76,599
-27,274
| -26% | -$1.26M | ﹤0.01% | 1615 |
|
|
2022
Q3 | $5.36M | Buy |
103,873
+19,112
| +23% | +$1.13M | 0.01% | 1332 |
|
|
2022
Q2 | $4.46M | Buy |
84,761
+29,649
| +54% | +$2.06M | ﹤0.01% | 1471 |
|
|
2022
Q1 | $4.74M | Buy |
55,112
+7,299
| +15% | +$600K | ﹤0.01% | 1550 |
|
|
2021
Q4 | $3.91M | Buy |
47,813
+4,980
| +12% | +$364K | ﹤0.01% | 1714 |
|
|
2021
Q3 | $2.85M | Buy |
42,833
+9,106
| +27% | +$646K | ﹤0.01% | 1846 |
|
|
2021
Q2 | $2.26M | Buy |
33,727
+9,374
| +38% | +$581K | ﹤0.01% | 2019 |
|
|
2021
Q1 | $1.27M | Buy |
24,353
+10,219
| +72% | +$517K | ﹤0.01% | 2338 |
|
|
2020
Q4 | $564K | Sell |
14,134
-3,868
| -21% | -$125K | ﹤0.01% | 2726 |
|
|
2020
Q3 | $441K | Sell |
18,002
-8,365
| -32% | -$214K | ﹤0.01% | 2721 |
|
|
2020
Q2 | $478K | Buy |
26,367
+1,379
| +6% | +$27.2K | ﹤0.01% | 2615 |
|
|
2020
Q1 | $360K | Sell |
24,988
-21,734
| -47% | -$624K | ﹤0.01% | 2657 |
|
|
2019
Q4 | $1.78M | Buy |
46,722
+14,303
| +44% | +$428K | ﹤0.01% | 1895 |
|
|
2019
Q3 | $717K | Buy |
32,419
+13,417
| +71% | +$286K | ﹤0.01% | 2400 |
|
|
2019
Q2 | $393K | Sell |
19,002
-22,075
| -54% | -$509K | ﹤0.01% | 2836 |
|
|
2019
Q1 | $1.19M | Buy |
41,077
+26,993
| +192% | +$666K | ﹤0.01% | 2098 |
|
|
2018
Q4 | $241K | Hold |
14,084
| – | – | ﹤0.01% | 2998 |
|
|
2018
Q3 | $401K | Sell |
14,084
-150
| -1% | -$4.95K | ﹤0.01% | 2855 |
|
|
2018
Q2 | $478K | Buy |
14,234
+150
| +1% | +$4.66K | ﹤0.01% | 2724 |
|
|
2018
Q1 | $342K | Sell |
14,084
-21,199
| -60% | -$422K | ﹤0.01% | 2808 |
|
|
2017
Q4 | $535K | Buy |
35,283
+19,145
| +119% | +$269K | ﹤0.01% | 2496 |
|
|
2017
Q3 | $265K | Buy |
16,138
+5,073
| +46% | +$86K | ﹤0.01% | 2866 |
|
|
2017
Q2 | $214K | Buy |
+11,065
| New | +$193K | ﹤0.01% | 2939 |
|
|
2013
Q3 | – | Sell |
-10,914
| Closed | -$503K | – | 1975 |
|
|
2013
Q2 | $503K | Buy |
+10,914
| New | +$489K | ﹤0.01% | 1514 |
|
Other funds holding THC
GCM
Raymond James & Associates's THC Position: Q3 2024 in Review
Raymond James & Associates increased its Tenet Healthcare (THC) stake by 25% in Q3 2024, buying an estimated $3.93M and bringing the position to 130,485 shares worth $21.7M. The position accounts for 0.01% of the portfolio, ranked #776.
Raymond James & Associates first reported a position in THC in Q2 2013 and has held it in 31 quarters since. 603 funds tracked by Wall St. Rank hold THC as of Q3 2024.
- Raymond James & Associates held 130,485 shares of Tenet Healthcare worth $21.7M as of Q3 2024.
- Raymond James & Associates bought 26,011 Tenet Healthcare shares in Q3 2024, an estimated $3.93M.
- Tenet Healthcare made up 0.01% of Raymond James & Associates's portfolio in Q3 2024, its #776 holding.
- Raymond James & Associates first reported a position in Tenet Healthcare in Q2 2013 and has held it in 31 quarters since.
- 603 funds tracked by Wall St. Rank held Tenet Healthcare as of Q3 2024.
Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.